Earn CME/CE in your profession:

Continuing Education Activity

The uses of niacin are yet to be fully comprehended and embraced. This activity assists in improving knowledge of the benefits niacin has to offer, not only for treatment but also in decreasing the incidence of certain diseases. This activity reviews the pharmacokinetic, administration, indications, contraindications, adverse effects, monitoring, toxicity, and, most importantly, how to enhance interprofessional team outcomes by effectively monitoring the use of this medication.


  • Describe the indications for initiating therapy with niacin.
  • Explain the pharmacokinetics and administration of niacin.
  • Outline niacin's adverse effects, contraindications, and toxicity.
  • Review why interprofessional teamwork among members of the healthcare field is necessary for educating patients taking niacin.


Niacin (a combination of nicotinic acid and nicotinamide), a B vitamin (vitamin B3), is a pharmacotherapeutic agent that has been used since 1955, making it the oldest pleiotropic hypolipidemic agent.[1] The vitamin plays a role in both neuroprotection and neuronal death, giving it the utmost importance in the proper functioning of the central nervous system (CNS), neuronal development, and function.[2]

Niacin has seen extensive use, alone or in combination, with statin medications (hydroxymethyl glutaryl coenzyme A reductase inhibitors) in the reduction of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL), and lipoprotein levels. Moreover, niacin is the most potent agent used to increase plasma high-density lipoprotein (HDL) cholesterol.[3] In patients with diabetes mellitus or mixed dyslipidemia, niacin has demonstrated in clinical trials that it can counterbalance cardiovascular risk in this patient population, decreasing cardiovascular morbidity and mortality, especially when combined with statin drugs.[4]

Niacin being such a pleiotropic agent still possesses properties that remain uncovered. Some other studied uses of niacin other than those stated above include the following.[5] It decreases  the incidence of cardiovascular events, premature aging, age-associated neurological disorders such as[6]

  • Arthritis[6]
  • Alzheimer disease
  • Huntington disease
  • Schizophrenia[7]
  • Amyotrophic lateral sclerosis
  • Muscular atrophy
  • hyperphosphatemia in chronic kidney disease[8]
  • Parkinson disease
  • Squamous cell carcinoma[9]
  • It also has therapeutic use in treating diabetic encephalopathy, malignant glioma, neurodegenerative diseases[10]
  • Circadian rhythm and metabolism regulation through sirtuins
  • Intracellular calcium regulation

Mechanism of Action

After undergoing biochemical reactions in the mitochondria with nicotinamide and tryptophan, niacin forms nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP). NAD and NADP are the active forms of niacin which, when reduced to NAD(H) and NADP(H) respectively, participate in catabolic redox reactions and are cofactors in anabolic redox reactions.

Although niacin has been in use for many years, its beneficial pleiotropic effects make it challenging to fully grasp its mechanism of action. However, a targeted mechanism of action based on certain effects niacin has in the human body are:

  1. Lipid metabolism: Lipid-lowering ability of niacin is very diverse and still under investigation. One proposed mechanism is the action of niacin's antilipolytic effect, thought to be mediated via nicotinic acid receptors. An alternate mechanism recently uncovered is the ability of niacin to speed up the intracellular degradation of Apolipoprotein B (ApoB) containing lipoproteins, such as VLDL and LDL, by inhibiting triglyceride synthesis. Also, niacin inhibits diacylglycerol acyltransferase 2 (DGAT2), thereby decreasing hepatic triglyceride synthesis. A suggested mechanism for increasing HDL-cholesterol levels is that niacin decreases the degradation of ApoA-I-containing lipoproteins and increases peroxisome proliferator-activated receptor γ (PPARγ) expression and enhances PPARγ transcriptional activity in macrophages.[11] Levels of free fatty acids become lowered via niacin's downregulating action of cyclic adenosine monophosphate. By doing so, it decreases the most important intracellular mediator of pro-lipolytic stimuli.[12]
  2. Increased fasting glycemia: This is thought to be through the roles of niacin-responsive G protein-coupled receptor (GPR109a) and plasma-free fatty acids (FFAs). Though details of the mechanism are yet to be fully uncovered, research has observed a direct relationship has between insulin resistance in muscles and high FFA (in the form of lipid overload) concentrations in non-adipose tissues. Also, intestinal cells in vivo are shown to increase their local glucose uptake when GPR109a gets stimulated by niacin, which may contribute to loss of glycemic control.[13]
  3. Aging-related process and pathologies: Though yet fully uncovered, the mechanism of action through current research may be the inverse relation between nicotinamide adenine dinucleotide (NAD) concentrations and dietary niacin intake. Researchers have demonstrated that reduced intracellular NAD concentrations lead to the loss of a cell's power to undergo division and growth, leading to cell aging and death. NAD-dependent enzymes such as sirtuin proteins and poly(ADP-ribose) polymerase (PARP) provide continuous protection of the genome and are also necessary for the repair of damaged DNA. Researchers observed increased cancer incidence and reactive oxygen species with decreased PARP. Also, lifespan-extending effects of caloric restriction, mediated by sirtuins, have been associated with premature aging and disorders like Huntington and other age-associated neurological disorders in cells with defective sirtuins.[14]
  4. Malignant glioma: Niacin may inhibit glioma cell invasion in vivo and in vitro. Epithelial-mesenchymal transition (EMT) is involved in the process of cell migration, adhesion, and polarity; it also has involvement in the downregulation of E-cadherin, an epithelial marker, and upregulation of Snail1, a mesenchymal marker, both processes which are important to the normal developmental of mesoderm and neural crest migration. Research has found tumor cells to have EMT-like processes, which give them the ability to recur and cause immunosuppression and cell invasion. The degradation of Snail1, an EMT-promoting transcription factor that leads to invasion of U251 glioblastoma multiforme cells, was found to be facilitated in cells with niacin treatment, thus leading to a decrease in tumor invasion.[15][16]


Niacin is available in two chemical forms. As nicotinic acid only, used for hyperlipoproteinemia or peripheral vascular disease. Another form is both nicotinic acid and nicotinamide (niacinamide), used for nutritional supplementation or pellagra.

  • Oral extended-release tablets come in 250 mg, 500 mg, 750 mg, 1000 mg, and 3000 mg strengths. Dosing of 1 to 3 grams/day was found to reduce serum LDL cholesterol and increase serum HDL cholesterol.[17] Research showed that a formulation of modified release niacin and crystalline immediate-release niacin offered similar results.[4]
  • Immediate-release tablets are available in formulation ranging from 50 mg to 500 mg. Initial dosing should be as low as possible to decrease adverse effect reactions and slowly titrated, preferably no more than 500 mg over four weeks to the patient’s response and tolerance.
  • Reverses in insulin resistance induced by lipid overload and rapid reduction of plasma FFA were observed with acute administration of niacin.[13]
  • At the time of niacin administration, patients should avoid alcohol as it may increase the risk of pruritus and flushing. In addition, niacin therapy is not recommended in patients who chronically misuse alcohol due to an increased risk of hepatotoxicity.

Recommended Dosage for Pellagra


  • Oral dosage (nicotinic acid or nicotinamide/niacinamide): Up to 500 mg/day orally, depending on the severity of niacin deficiency.
  • Intravenous or Intramuscular Dosage: 50 to 100 mg intramuscular five times daily, or 25 to 100 mg given by slow intravenous infusion twice daily, depending on the severity of niacin deficiency. Maximum: 500 mg/daily.


  • Dosing is up to 300 mg/day given by slow intravenous infusion, depending on the severity of niacin deficiency.

Recommended Dosage for Hypercholesterolemia, Mixed Dyslipidemia or Hypertriglyceridemia, Type IV or V

  • Normal dosing is 1500 to 3000 mg/day orally, divided two or three times daily.
  • Starting dose: 250 mg orally at bedtime, with a gradual increase of 250 mg/day every 4 to 7 days up to 2000 mg/day. 
  • After two months, the dosage may be increased to 250 to 500 mg/day every 2 to 4 weeks, with a maximum of 6000 mg/day. 
  • Note: 325 mg aspirin 30 minutes before a dose may reduce flushing; The medication should be given without food.

Pregnancy Considerations

  • Niacin is FDA Pregnancy Category C. When used at high doses to treat conditions such as dyslipidemia, niacin may cause harm to an unborn fetus.

Breastfeeding Considerations

  • Harm may result in a nursing baby as niacin can pass into breast milk; therefore, nursing mothers should avoid the drug.

Adverse Effects

Common Reactions

Flushing: Niacin often causes generalized pruritus, and a burning sensation is usually limited to the face and chest and lasts 20 to 30 minutes. This adverse reaction, however, decreases in frequency and severity with time.[4] Pretreatment of 30 minutes with aspirin (up to 325 mg) can help counter this side effect. Laropiprant, a potent, selective antagonist of prostaglandin D2( PGD2)-receptor subtype-1, not only helps reduce this side effect of niacin but allows for optimal pharmacological dosing if needed.[18]

One reaction to consider is niacin’s effects (whether used alone or combined with statin medications) on glycemic control in patients with dyslipidemia, regardless of their diabetes mellitus status. In non-diabetic patients with dyslipidemia, on average, five years of niacin therapy, whether used alone or in laropiprant combination therapy, was associated with a 34% increased risk of developing diabetes.[19] Also, niacin administration has been demonstrated to increase fasting glycemic levels in patients with diabetes. Avoiding niacin therapy has been recommended in patients with metabolic syndrome or diabetes.[13][5]

Other adverse effects include hyperuricemia, gastrointestinal disorders, rash, increased homocysteine levels, hypotension, dyspepsia, elevations in AST and ALT, nausea, vomiting, and paresthesias.[5][1]

Serious Adverse Reactions

Peptic ulcer disease, arrhythmias, anaphylaxis, hepatotoxicity, hepatic necrosis, fulminant, macular edema[1]


Contraindications to niacin include the following conditions:

  • Patients with active peptic ulcer disease
  • Patients who have active liver disease or present with unexplained and persistent elevations in hepatic transaminases
  • Patients with hypersensitivity to niacin or any component of this medication
  • Patients with arterial bleeding


  • Laboratory monitoring is recommended in patients on niacin therapy due to its diverse side effects.
  • In pre-diabetes or diabetic patients, frequent monitoring of blood glucose is necessary as niacin can increase fasting blood glucose. Patients on diabetic medications, such as acarbose, albiglutide, alogliptin, glipizide, or insulin, should also have blood glucose monitored frequently.[19] 
  • Niacin can cause an increase in uric acid, thus exerting an antagonist effect on medications for gouts, such as pegloticase and allopurinol.
  • Niacin exerts an additive reaction with blood pressure medications (amlodipine clozapine, bisoprolol, diltiazem), opioids (morphine, oxycodone, tramadol, methadone), antipsychotics (quetiapine, risperidone) phosphodiesterase type 5 inhibitor (tadalafil), thus leading to hypotension. Frequent blood pressure checking is recommended. Also, niacin, in combination with some beta-blockers, may decrease its antihyperlipidemic efficacy.
  • Niacin can increase the risk of bleeding by exerting an additive effect. Niacin has shown to not only cause a reduction in platelet counts (mean of -11% with 2000 mg) but to increase prothrombin time (mean of approximately +4%), leading to bleeding, especially when combined with anticoagulants such as apixaban, caplacizumab, or warfarin. Thus, a blood coagulation panel should be a routine test.
  • Niacin also exerts an additive effect when combined with ceritinib, diazoxide leading to hyperglycemia.
  • Phosphorus levels also require monitoring in patients at risk for hypophosphatemia as niacin can cause a decrease in phosphorus levels (mean of -13% with 2000 mg).


In pharmacological doses (e.g., 1000 to 3000 mg/day), flushing reaction associated with its crystalline nicotinic acid component (not nicotinamide) is the most common and studied the toxicity of niacin, which is both person-to-person and dose-dependent.[4] Other symptoms of toxicity may include dizziness, upset stomach, redness, itching, nausea, and vomiting.

Enhancing Healthcare Team Outcomes

Niacin is a pharmacotherapeutic pleiotropic agent with properties still yet to be fully understood. It is encouraged that interprofessional healthcare team members (clinicians, pharmacists, nurse practitioners, physician assistants, primary care providers, nurses) stay updated on niacin's properties and side effects uncovered by ongoing research. Niacin can cause flushing, a significant adverse impact that significantly affects its compliance in patients. Knowing how to titrate from a minimal dose will help minimize such unwanted effects and benefit patient health outcomes. Close monitoring and periodic blood work on initiating or increasing the dosage of niacin is necessary as it is known to increase the risk of bleeding, hypotension, hyperuricemia, and cause alterations in glycemic control. Its adverse effect on glycemic control in patients with dyslipidemia, both with or without diabetes, is one of its most concerning effects as it may cause diabetes in predisposed patients or make the management of diabetes a challenge. Using an interprofessional approach with each discipline contributing from their area of expertise will result in better patient outcomes and fewer adverse effects from niacin. [Level 5]



Soraya Djadjo


Tushar Bajaj


3/20/2023 12:06:28 AM



Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid? Current vascular pharmacology. 2011 Jul 1:9(4):521-30     [PubMed PMID: 21314634]


Fricker RA, Green EL, Jenkins SI, Griffin SM. The Influence of Nicotinamide on Health and Disease in the Central Nervous System. International journal of tryptophan research : IJTR. 2018:11():1178646918776658. doi: 10.1177/1178646918776658. Epub 2018 May 21     [PubMed PMID: 29844677]


Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clinic proceedings. 2008 Apr:83(4):470-8. doi: 10.4065/83.4.470. Epub     [PubMed PMID: 18380993]


Wierzbicki AS. Niacin: the only vitamin that reduces cardiovascular events. International journal of clinical practice. 2011 Apr:65(4):379-85. doi: 10.1111/j.1742-1241.2011.02630.x. Epub     [PubMed PMID: 21401825]


Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Current vascular pharmacology. 2011 Jul 1:9(4):385-400     [PubMed PMID: 21314635]


HOFFER A. Treatment of arthritis by nicotinic acid and nicotinamide. Canadian Medical Association journal. 1959 Aug 15:81(4):235-8     [PubMed PMID: 14402370]


Xu XJ,Jiang GS, Niacin-respondent subset of schizophrenia – a therapeutic review. European review for medical and pharmacological sciences. 2015;     [PubMed PMID: 25855923]


Taketani Y, Masuda M, Yamanaka-Okumura H, Tatsumi S, Segawa H, Miyamoto K, Takeda E, Yamamoto H. Niacin and Chronic Kidney Disease. Journal of nutritional science and vitaminology. 2015:61 Suppl():S173-5. doi: 10.3177/jnsv.61.S173. Epub     [PubMed PMID: 26598845]


Park SM, Li T, Wu S, Li WQ, Weinstock M, Qureshi AA, Cho E. Niacin intake and risk of skin cancer in US women and men. International journal of cancer. 2017 May 1:140(9):2023-2031. doi: 10.1002/ijc.30630. Epub 2017 Feb 14     [PubMed PMID: 28152570]


Motawi TK, Darwish HA, Hamed MA, El-Rigal NS, Aboul Naser AF. Coenzyme Q10 and niacin mitigate streptozotocin- induced diabetic encephalopathy in a rat model. Metabolic brain disease. 2017 Oct:32(5):1519-1527. doi: 10.1007/s11011-017-0037-x. Epub 2017 May 30     [PubMed PMID: 28560538]


Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annual review of pharmacology and toxicology. 2008:48():79-106     [PubMed PMID: 17705685]


Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F. New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert review of cardiovascular therapy. 2010 Oct:8(10):1457-67. doi: 10.1586/erc.10.116. Epub     [PubMed PMID: 20936932]


Meyer-Ficca M, Kirkland JB. Niacin. Advances in nutrition (Bethesda, Md.). 2016 May:7(3):556-8. doi: 10.3945/an.115.011239. Epub 2016 May 16     [PubMed PMID: 27184282]

Level 3 (low-level) evidence


Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in cell biology. 2014 Aug:24(8):464-71. doi: 10.1016/j.tcb.2014.04.002. Epub 2014 Apr 29     [PubMed PMID: 24786309]


Li J, Qu J, Shi Y, Perfetto M, Ping Z, Christian L, Niu H, Mei S, Zhang Q, Yang X, Wei S. Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Scientific reports. 2017 Mar 3:7():43173. doi: 10.1038/srep43173. Epub 2017 Mar 3     [PubMed PMID: 28256591]


Yang X, Mei S, Niu H, Li J. Nicotinic acid impairs assembly of leading edge in glioma cells. Oncology reports. 2017 Aug:38(2):829-836. doi: 10.3892/or.2017.5757. Epub 2017 Jun 27     [PubMed PMID: 28656206]


Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. Vascular health and risk management. 2014:10():279-90. doi: 10.2147/VHRM.S58694. Epub 2014 May 7     [PubMed PMID: 24855368]


Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular health and risk management. 2009:5():901-8     [PubMed PMID: 20016845]


Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart (British Cardiac Society). 2016 Feb:102(3):198-203. doi: 10.1136/heartjnl-2015-308055. Epub 2015 Sep 14     [PubMed PMID: 26370223]

Level 1 (high-level) evidence